<DOC>
	<DOCNO>NCT01505439</DOCNO>
	<brief_summary>This study investigate effect solifenacin urgency urinary incontinence symptom incontinence quality-of-life ( I-QoL ) female patient clinically significant stress urinary incontinence accompany urgency urinary incontinence .</brief_summary>
	<brief_title>A Study Estimate Efficacy Safety Solifenacin Female With Stress Urinary Incontinence Urgency Urinary Incontinence</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Patients select meet one criterion Patients positive cough provocation test Based 3day void diary , patient : Urinary frequency ( eight micturition per day 24 hour ) Urinary urgency ( two episode per day 24 hour ) Urge incontinence ( three episodes 3 day ) Breastfeeding woman female childbearing potential intention become pregnant study Postvoid residual urine volume ( PRV ) 150 cc Patients experience acute ureteral obstruction require indwell catheter Patients experience clinically significant pelvic organ prolapse low urinary tract surgery within 6 month prior initiation present study Patients underwent urinary incontinence operation within 1 year Any condition , opinion investigator , contraindication anticholinergic treatment , include severe narrowangled glaucoma , urinary retention , gastric retention , severe myasthenia , severe hepatic insufficiency severe ulcerative colitis Significant hepatic renal disease , define great twice upper limit reference range serum concentration aspartate aminotransferase ( AST [ SGOT ] ) , alanine aminotransferase ( ALT [ SGPT ] ) , alkaline phosphatase creatinine Patients neurological disorder stroke , multiple sclerosis , spinal cord injury , Parkinson 's disease Patients use indwell catheter practice intermittent selfcatheterization Recurrent UTIs define treat symptomatic UTIs 3 time last year Symptomatic acute urinary tract infection ( UTI ) runin period Patients receive follow prohibit concomitant drug within 14 day prior randomization : Treatment perform within 14 day precede randomization , expect initiate treatment study : Any anticholinergic trial drug Any drug treatment overactive bladder . Estrogen treatment start 2 month prior inclusion allow Patients take unstable dosage drug anticholinergic side effect , expect start treatment study Patients chronic constipation history severe constipation Treatment potent CYP3A4 inhibitor , cyclosporine , vinblastine , macrolide antibiotic ( e.g . erythromycin , clarithromycin , azithromycin ) antifungal agent ( e.g . ketoconazole , itraconazole , micronazole ) Sexually active female childbearing potential use reliable contraception least 1 month prior study initiation agree use method entire study period least 1 month thereafter . Reliable contraceptive method define intrauterine device ( IUDs ) , combination type contraceptive pill , hormonal implant , double barrier method , injectable contraceptive , surgical procedure ( tubal ligation vasectomy ) , continence Any condition , opinion investigator , make patient unsuitable inclusion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>solifenacin</keyword>
	<keyword>bladder symptom</keyword>
</DOC>